Humacyte, Inc. (NASDAQ:HUMA) Receives $11.71 Average PT from Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have earned a consensus recommendation of "Buy" from the eight analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $11.71.

Several equities analysts have commented on the stock. Benchmark lowered their price objective on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. HC Wainwright began coverage on shares of Humacyte in a research note on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price target on the stock. Wall Street Zen downgraded shares of Humacyte from a "hold" rating to a "sell" rating in a research report on Saturday. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a research report on Monday, June 9th.

Humacyte Stock Down 1.7%

Shares of NASDAQ HUMA traded down $0.04 during midday trading on Thursday, hitting $2.37. The stock had a trading volume of 2,720,709 shares, compared to its average volume of 3,856,671. The business's 50 day moving average is $1.91 and its 200-day moving average is $3.16. The company has a market cap of $367.63 million, a P/E ratio of -1.77 and a beta of 2.00. Humacyte has a 52 week low of $1.15 and a 52 week high of $9.79.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million. As a group, analysts expect that Humacyte will post -1.27 EPS for the current fiscal year.

Insider Transactions at Humacyte

In other news, CFO Dale A. Sander acquired 20,000 shares of Humacyte stock in a transaction on Thursday, April 10th. The stock was bought at an average cost of $1.53 per share, with a total value of $30,600.00. Following the completion of the purchase, the chief financial officer now owns 40,600 shares of the company's stock, valued at $62,118. This represents a 97.09% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kathleen Sebelius purchased 50,000 shares of Humacyte stock in a transaction dated Tuesday, April 8th. The stock was bought at an average cost of $1.32 per share, with a total value of $66,000.00. Following the completion of the transaction, the director now directly owns 91,207 shares of the company's stock, valued at $120,393.24. This represents a 121.34% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders bought 83,993 shares of company stock worth $118,224. 5.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Humacyte

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Humacyte by 10.8% in the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after acquiring an additional 543,995 shares during the last quarter. Heights Capital Management Inc. bought a new position in shares of Humacyte in the first quarter valued at about $6,863,000. Woodline Partners LP raised its holdings in shares of Humacyte by 38.7% in the first quarter. Woodline Partners LP now owns 3,950,000 shares of the company's stock valued at $6,735,000 after buying an additional 1,101,198 shares during the last quarter. RA Capital Management L.P. acquired a new stake in Humacyte in the first quarter worth about $5,648,000. Finally, Geode Capital Management LLC increased its position in Humacyte by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company's stock worth $10,785,000 after purchasing an additional 94,915 shares during the period. Institutional investors own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.